Astute Medical, Inc. Highlights Upcoming Presentation Of Study Examining Risk Of AKI In Neurologic Patients

News provided by

Astute Medical, Inc.

07 Oct, 2015, 11:00 GMT

SAN DIEGO, Oct. 7, 2015 /PRNewswire/ -- Astute Medical, Inc., developer of the NephroCheck® Test, today highlighted an abstract to be presented October 8, 2015 at the 13th Neurocritical Care Society (NCS) Annual Meeting relating to the prediction of acute kidney injury (AKI) in neurologic patients using two urinary cell cycle arrest biomarkers. The meeting will take place October 7 through October 10 in Phoenix.

Dr. Paul McCarthy of the University of Maryland Medical Center will present the abstract "Cell Cycle Arrest Biomarkers Predictive of Early Acute Kidney Injury in Critically Ill Neurologic Patients."

"Neurologic conditions in critically ill patients are highly complex, and evaluation of a threat as grave as AKI is crucial to managing care," said Paul McPherson, Astute Medical chief scientific officer. "We are pleased to see research addressing this important disease category."

Acute kidney injury is increasingly prevalent.1 Fifty percent of patients in the ICU will contract some stage of AKI,2 a condition associated with a 10-fold increase in hospital mortality rates and a higher rate of chronic kidney disease among post-op patients. 3 Unlike other potentially catastrophic events, such as myocardial infarction, AKI often has no signs or symptoms, making risk assessment via traditional methods difficult.4 

The NephroCheck® Test is designed to detect the two urinary biomarkers featured in the abstract, TIMP-2 and IGFBP-7. Both biomarkers are involved in a wide array of responses to tissue insult (inflammation, oxidative stress, ultra-violet radiation, drugs and toxins) 5-7 and are thought to be involved in G1 cell-cycle arrest during the earliest phases of injury to the kidney. 8 With results in just 20 minutes, the NephroCheck® Test helps healthcare professionals evaluate intensive care patients' risk of moderate to severe acute kidney injury in the next 12 hours. The test was created for use alongside clinical evaluation of intensive care patients over 21 who have or have had acute cardiovascular and/or respiratory compromise in the past 24 hours.

Once at-risk patients have been identified and their risk stratified, healthcare professionals can implement kidney-sparing strategies to potentially temper the severe consequences associated with AKI.

About Astute Medical, Inc.

Selected to the 2014 Fierce 15 by Fierce Medical Devices, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests.

The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.

Astute Medical is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025. 

Astute Medical's NephroCheck® Test received 510(k)-clearance through the FDA's de novo classification process in September 2014. The test was CE-marked in 2012 and is available in Europe.

For additional information, please visit AstuteMedical.com.

For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see astutemedical.com/about/intellectual-property. PN0503 Rev A 2015/10/05

References

  1. Kam Tao Li P, Burdmann EA, Mehta RL. Acute kidney injury: Global health alert. J Nephropathol. 2013;2(2):90-97.
  2. Mandelbaum T, Scott DJ, Lee J, et al. Outcome of critically ill patients with acute kidney injury using the AKIN criteria. Crit Care Med. 2011;39(12):2659-2664.
  3. Hobson C, Ozrazgat-Baslanti T, Kuxhausen A, et al. Cost and mortality associated with postoperative acute kidney injury. Ann Surg. 2014;00:1-8.
  4. Ronco C, Ricci Z. The concept of risk and the value of novel markers of acute kidney injury. Crit Care. 2013;17:117-118.
  5. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene. 2004;337:1-13.
  6. Seo DW, Li H, Qu CK, et al. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem. 2006;281:3711-3721.
  7. Price PN, Safirstein RL, Megyesi J. The cell cycle and acute kidney injury. Kidney Int. 2009;76:604-613.
  8. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.

Related Links

http://www.astutemedical.com